All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
Introducing
Now you can personalise
your Multiple Myeloma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Bookmark this article
During the 25th Congress of the European Hematology Association (EHA), the MM Hub spoke to Mehmet Samur, Dana-Farber Cancer Institute, Boston, US. We asked, What are the key biological and clinical characteristics of patients with ultra-low-risk MM?
What are the key biological and clinical characteristics of patients with ultra-low-risk MM?
Until now, the primary focus of genomic studies in the MM setting has been high-risk disease. Here, Mehmet Samur discusses a study in which patients with newly diagnosed MM underwent whole genome sequencing with the aim to define low-risk patients.
Subscribe to get the best content related to multiple myeloma delivered to your inbox